drugset / Trial / NCT02513667
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
Phase 2
Terminated
14 enrolled
University of Texas Southwestern Medical Center
Novartis Pharmaceuticals · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see if Ceritinib can target ALK in non-small cell lung cancer and slow down cancer growth and prevent it from spreading.
Timeline
- Start
- 2015-11
- Primary completion
- 2020-05-29
- Completion
- 2021-05-29
Outcome
Outcome not reported
Stopped: “The study was terminated after UTSW was informed by Novartis that further support for the study would not be provided”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceritinib | Small molecule | 750 mg | — |